Cover Image

Quantitative systems pharmacology model for Alzheimer's disease to predict the effect of aducanumab on brain amyloid

Abstract Alzheimer's disease (AD) is an irreversible, progressive brain disorder that impairs memory and cognitive function. Dysregulation of the amyloid‐β (Aβ) pathway and amyloid plaque accumulation in the brain are hallmarks of AD. Aducanumab is a human, immunoglobulin gamma 1 monoclonal ant...

Full description

Saved in:

Bibliographic Details
Main Authors:	Lin Lin (Author), Fei Hua (Author), Cristian Salinas (Author), Carissa Young (Author), Thierry Bussiere (Author), Joshua F. Apgar (Author), John M. Burke (Author), Kumar Kandadi Muralidharan (Author), Rajasimhan Rajagovindan (Author), Ivan Nestorov (Author)
Format:	Book
Published:	Wiley, 2022-03-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Population pharmacokinetics and standard uptake value ratio of aducanumab, an amyloid plaque-removing agent, in patients with Alzheimer's disease
by: Kumar Kandadi Muralidharan, et al.
Published: (2022)

Aducanumab and lecanemab - two novel antibodies against pathologic species of amyloid beta in the treatment of Alzheimer's disease
by: Jakub Wojcieszak
Published: (2023)

Aducanumab for Alzheimer's disease: The never‐ending story that nurses should know
by: Joel Petch, et al.
Published: (2021)

Topical Insights Into the Post-Approval Controversies of Aducanumab
by: Dhiraj Kumar, et al.
Published: (2021)

Aducanumab: evidence from clinical trial data and controversies
by: Rajesh R Tampi, et al.
Published: (2021)

Quantitative systems pharmacology model of the amyloid pathway in Alzheimer's disease: Insights into the therapeutic mechanisms of clinical candidates
by: Vidya Ramakrishnan, et al.
Published: (2023)

Quantitative Systems Pharmacology Model of a Masked, Tumor‐Activated Antibody
by: Mark Stroh, et al.
Published: (2019)

A combined physiologically‐based pharmacokinetic and quantitative systems pharmacology model for modeling amyloid aggregation in Alzheimer's disease
by: Hugo Geerts, et al.
Published: (2023)

Effect of Indigofera tinctoria on ?-amyloid (25-35) mediated Alzheimer's disease in mice: Relationship to antioxidant activity
by: G. Balamurugan, P. Muralidharan
Published: (2010)

Amyloid-beta clearance in Alzheimer's disease
by: Robert Marr
Published: (2015)

Integrating experimentation and quantitative modeling to enhance discovery of beta amyloid (Aβ) lowering therapeutics for Alzheimer's disease
by: Yasong eLu
Published: (2012)

Quantitative systems pharmacology model of GITR‐mediated T cell dynamics in tumor microenvironment
by: Yan Ji, et al.
Published: (2023)

Accelerated Approval of Highly Expensive Disease-modifying Agents: Lessons Learned From the Aducanumab Approval
by: Santenna Chenchula, et al.
Published: (2022)

β-Amyloid: The Key Peptide in the Pathogenesis of Alzheimer's Disease
by: Xiaojuan eSun, et al.
Published: (2015)

Effect of berberine on cognitive function and β-amyloid precursor protein in Alzheimer's disease models: a systematic review and meta-analysis
by: Jia-Yang Liu, et al.
Published: (2024)

The cost and benefit of targeting amyloid plaques to treat alzheimer's disease
by: Marisa E Franklin, et al.
Published: (2023)

Doxycycline for Alzheimer's Disease: Fighting β-Amyloid Oligomers and Neuroinflammation
by: Claudia Balducci, et al.
Published: (2019)

Quantitative systems pharmacology modeling provides insight into inter‐mouse variability of Anti‐CTLA4 response
by: Wenlian Qiao, et al.
Published: (2022)

Near-infrared fluorescent probes for imaging of amyloid plaques in Alzheimer׳s disease
by: Hongjuan Tong, et al.
Published: (2015)

Molecular Approaches to the Treatment, Prophylaxis, and Diagnosis of Alzheimer's Disease: Tangle Formation, Amyloid-β, and Microglia in Alzheimer's Disease
by: Kazuyuki Takata, et al.
Published: (2012)

Exploring the Involvement of the Amyloid Precursor Protein A673T Mutation against Amyloid Pathology and Alzheimer's Disease in Relation to Therapeutic Editing Tools
by: Gabriela Dumitrita Stanciu, et al.
Published: (2022)

Amyloid-beta clearance in Alzheimer's disease: Does exercise play a role?
by: Reza Gharakhanlou, et al.
Published: (2020)

The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint
by: Linus Jönsson, et al.
Published: (2023)

Should we lower or raise levels of amyloid-β in the brains of Alzheimer patients?
by: Bruno P. Imbimbo, et al.
Published: (2022)

Amyloid precursor protein in peripheral granulocytes as a potential biomarker for Alzheimers disease
by: Xiaonan Wang, et al.
Published: (2016)

Amyloid precursor protein in peripheral granulocytes as a potential biomarker for Alzheimer's disease
by: Xiaonan Wang, et al.
Published: (2016)

Anti-Amyloid-β Monoclonal Antibodies: Recent Therapeutic Strategies for Alzheimer's Disease
by: Maria Teresa Cruz, et al.
Published: (2022)

Therapeutic effect of Melissa officinalis in an amyloid-β rat model of Alzheimer's disease
by: Siamak Beheshti, et al.
Published: (2018)

Small-Molecule Amyloid Beta-Aggregation Inhibitors in Alzheimer's Disease Drug Development
by: Sharmin Reza Chowdhury, et al.
Published: (2019)

Anti-inflammatory Activity of a Polypeptide Fraction From Achyranthes bidentate in Amyloid β Oligomers Induced Model of Alzheimer's Disease
by: Xiangyu Ge, et al.
Published: (2021)

Sleep and β-Amyloid Deposition in Alzheimer Disease: Insights on Mechanisms and Possible Innovative Treatments
by: Susanna Cordone, et al.
Published: (2019)

The Neuroprotective Action of Amidated-Kyotorphin on Amyloid β Peptide-Induced Alzheimer's Disease Pathophysiology
by: Rita F. Belo, et al.
Published: (2020)

Oxidative Stress and Beta Amyloid in Alzheimer's Disease. Which Comes First: The Chicken or the Egg?
by: Elena Tamagno, et al.
Published: (2021)

Role of Lipocalin-2 in Amyloid-Beta Oligomer-Induced Mouse Model of Alzheimer's Disease
by: Heeyoung Kang, et al.
Published: (2021)

Subregional Density of Neurons, Neurofibrillary Tangles and Amyloid Plaques in the Hippocampus of Patients With Alzheimer's Disease
by: Diana Furcila, et al.
Published: (2019)

Gut dysbiosis aggravates cognitive deficits, amyloid pathology and lipid metabolism dysregulation in a transgenic mouse model of Alzheimer's disease
by: Chang Qu, et al.
Published: (2023)

Traditional Chinese Medicine: Role in Reducing β-Amyloid, Apoptosis, Autophagy, Neuroinflammation, Oxidative Stress, and Mitochondrial Dysfunction of Alzheimer's Disease
by: Shi-Yu Chen, et al.
Published: (2020)

β-Asarone Inhibits Amyloid-β by Promoting Autophagy in a Cell Model of Alzheimer's Disease
by: Nanbu Wang, et al.
Published: (2020)

Pathophysiological Roles of Amyloidogenic Carboxy-Terminal Fragments of the β-Amyloid Precursor Protein in Alzheimer's Disease
by: Keun-A Chang, et al.
Published: (2005)

Oligomeric amyloid-β targeted contrast agent for MRI evaluation of Alzheimer's disease mouse models
by: Jang Woo Park, et al.
Published: (2024)